unknown node
unknown node
unknown node
unknown node
unknown node
unknown node
unknown node
- unknown node
- unknown node
- unknown node
unknown node
unknown node
- unknown node
- unknown node
- unknown node
- unknown node
unknown node
Bloodborne Pathogens · Clinical Reagents · Application Insights · Procurement & Buyer's Guide
unknown node
unknown node
unknown node
unknown node
unknown node
unknown node
NAT economics for mid-size blood banks are decided at design time: pool size modelled against your own prevalence, window-period claims per marker pinned in the contract, and workflow integration costs priced before signing.
Target audienceBlood Bank Director, Procurement, Finance
Compiled from public manufacturer materials and regulatory sources. Not independently verified and not reviewed by a named clinician.
2026-10-06
2026-10-06
professional use
FAQ
Nucleic acid amplification testing of blood donations to detect HIV, HBV, or HCV during the window period before serological markers appear, intercepting infections that antibody or antigen tests miss.
It is more sensitive, especially for HBV, but costs substantially more per donation. The right choice depends on local prevalence, budget, and how much window-period closure the programme needs to buy.
Workflow integration: tube handling, pool-to-donation mapping for lookback, and downtime recovery. These rarely appear in unit-price comparisons yet dominate the real cost of ownership.
Ask for the claim per marker, under your intended pool size, in writing — and file it as a contract annex. Claims are configuration-specific, and configurations differ between vendors.